重大事件
外國發行人報告
6-K
2026-06-24
Lakefront Biotherapeutics 於歐洲回購 7.7 萬股，涉資約 204 萬美元
AI 繁中摘要
6-K 申報文件 📄
Lakefront Biotherapeutics NV（Euronext & NASDAQ: LKFT，前稱 Galapagos）於 2026 年 6 月 23 日公佈，根據 2026 年 6 月 9 日宣布的股份回購計劃，在 2026 年 6 月 15 日至 19 日期間，於歐洲多邊交易平台（EXNT）合共回購 77,667 股普通股，平均買入價為每股 24.6586 歐元，總代價約 192 萬歐元（約 204 萬美元）。回購價格範圍介乎每股 24.00 歐元至 25.26 歐元。截至 2026 年 6 月 19 日收市，公司持有 116,204 股庫存股份。
公司簡介：Lakefront 為一家專注免疫及炎症領域的生物科技公司，核心資產 gamgertamig 是一種潛在 first-in-class BCMAxCD3 T 細胞銜接器，用於自身免疫疾病。公司具備靈活的交易能力及穩健資本狀況，持續篩選並推進高潛力資產。
對投資者而言，本次股份回購顯示管理層對公司價值及前景的信心，短期內或為股價提供支持。惟投資者需注意，回購計劃屬前瞻性陳述，實際執行取決於市場情況及相關風險，詳情可參閱公司向 SEC 提交的 20-F 年報及後續文件。
展開英文正文
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 77,667 Lakefront shares between 15 June 2026 and 19 June 2026, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
15/06/2026
EXNT
13,272
24.9331
330,912.10
24.7200
25.2200
16/06/2026
EXNT
16,400
24.5495
402,611.80
24.1200
25.2600
17/06/2026
EXNT
13,605
24.4212
332,250.43
24.0000
24.7800
18/06/2026
EXNT
16,960
24.8036
420,669.06
24.4800
25.1200
19/06/2026
EXNT
17,430
24.5966
428,718.74
24.3600
24.7600
Total
77,667
24.6586
1,915,162.13
24.3360
25.0280
As of market close on 19 June 2026, Lakefront holds 116,204 of its own ordinary shares.
About Lakefront BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology
company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The
Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class
BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong
capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient
impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:Investor Relations Sherri Spear+1
412 522 [email protected]
Forward-looking statementsThis press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often,
but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.